Skip to main content
MedPathMedPath Home
Clinical Trials/DRKS00023289
DRKS00023289
Not yet recruiting
Not Applicable

Prostate-specific Membrane Antigen (PSMA) expression in cervical carcinoma

niversitätsklinikum FreiburgKlinik für Frauenheilkunde0 sites100 target enrollmentOctober 16, 2020
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsC53.9Cervix uteri, unspecified

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
C53.9
Sponsor
niversitätsklinikum FreiburgKlinik für Frauenheilkunde
Enrollment
100
Status
Not yet recruiting
Last Updated
last year
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
October 16, 2020
End Date
TBD
Last Updated
last year
Study Type
Observational
Sex
Female

Investigators

Sponsor
niversitätsklinikum FreiburgKlinik für Frauenheilkunde

Eligibility Criteria

Inclusion Criteria

  • •Patients with a histologically secured invasive cervical carcinoma are included in this study . The cancerous pre\-stages surrounding the Tumor (cervical intraepithelial neoplasia, adenocarcinoma in situ) are also investigated.

Exclusion Criteria

  • •\- no declaration of consent
  • •\- other oncological disease
  • •\- adenosquamous, neuroendocrine (large or small cell), clear\-line or serous\-papillary carcinoma
  • •\- Cytostatic or radiotherapy administered before tissue sampling

Outcomes

Primary Outcomes

Not specified

Similar Trials

Completed
Not Applicable
Prostate-specific Membrane Antigen (PSMA) expression in endometrial cancerC54Malignant neoplasm of corpus uteri
DRKS00025005niversitätsklinikum Freiburg Klinik für Frauenheilkunde61
Not yet recruiting
Not Applicable
Prostate-specific membrane antigen (PSMA) expression in ovarian carcinomaC56Malignant neoplasm of ovary
DRKS00023240niversitätsklinikum Freiburg Klinik für Frauenheilkunde100
Recruiting
Phase 2
Prostate-Specific Membrane Antigen (PSMA) Intensity Can be Altered by Androgen and phospho-SrC Obstructiometastatic castration-resistant prostate cancerCancer - Prostate
ACTRN12621000611820St Vincent's Hospital, Sydney22
Recruiting
Phase 2
Expression of prostate specific membrane antigen (PSMA) in soft tissue sarcomas and urothelial cell carcinomas: implications for tumour-specific molecular imaging and treatment?bladder cancercohort 1: soft tissue cancercohort 2: transitional cell carcinomasoft tissue tumour1002838910004994
NL-OMON54064eids Universitair Medisch Centrum120
Not yet recruiting
Phase 1
Emerging digital imaging-guided theranostic therapy for newly diagnosed high risk prostate cancer patients: A feasibility studyProstate CancerCancer - Prostate
ACTRN12620001358932I-MED Radiology Network5